ALS Investment Fund

VectorY Therapeutics is a gene therapy company founded in August 2020 at the Amsterdam Science Park. The company focuses on developing innovative therapeutics, particularly vectorized antibodies, targeting central nervous system (CNS) and somatic disorders, with a special emphasis on muscle diseases. By integrating the strengths of antibodies and gene therapy, VectorY aims to create long-lasting therapeutic solutions for significant health challenges that lack adequate treatment options. Their platform is designed to facilitate scalable manufacturing processes that effectively target specific cell types and sub-cellular compartments while minimizing the risks associated with host immune response. This approach allows healthcare professionals to address critical areas of unmet medical need effectively.